Windsor's key strategy to reduce emissions 'too costly' without financial help
Council told staff in 2018 to create a program that would help 80 per cent of the city's homes become up to 50 per cent more energy efficient by 2041.
But a report to council now finds completing the goal of retrofitting 57,200 homes would take 100 years based on uptake in other retrofit programs.
The program is pitched in Windsor's Community Energy Plan as the most effective way to cut energy consumption and community-wide greenhouse gas emissions.
That's because 21 percent of community-wide emissions are from heating, cooling and powering houses that are on average 20 years older than Ontario's average.
But after years of study and design work, senior administration say the Windsor Residential Deep Energy Efficiency Retrofit (R-DEER) program is too expensive to implement and unlikely to achieve the initial target.
Windsor's Citizens Environment Alliance says not moving forward with the program would leave the city's climate-action efforts "in shambles."
How the program would work
The R-DEER plan staff developed would let homeowners borrow between $10,000 and $40,000, depending on the value of their home, to cover energy efficient upgrades with a low interest rate.
Some examples of projects the money could be spent on include energy efficient windows and doors, better insulation, and electric vehicle charging stations.
Homes would need to be at least 20 years old with a creditworthy homeowner.
City staff previously said the average home in Windsor was built in the 1960s and uses 20 per cent more energy than the average home in Ontario.
The proposed program would offer energy coaches that would guide people through financing and program options.
The city could also offer a grant to pay for energy audits to help owners understand the potential benefits of upgrades while reducing upfront costs.
People could use a Local Improvement Charge to pay for the retrofits, which is a loan tied to the property and repaid through property taxes.
How much it would cost
In the report to council, administration lays out a 10-year funding model aimed at making 80 per cent of Windsor homes 50 per cent more energy efficient.
The total cost would be $200-million, with $154-million over those 10 years being loans for work that the city is expected to recover.
However, Windsor's city treasurer Janice Guthrie warns the loans would require a partnership with a financial institution and would then be considered debt.
"That would really put a stranglehold on anything else we would be wanting to do in terms of capital projects for the city," said Guthrie.
"Some of those could be at jeopardy of not being able to move forward."
Administrating the plan would require 10 full-time equivalent jobs a few years after launching the program, according to the report to council.
Meeting initial goal would take 100 years
Staff also write that getting the uptake required to meet the emission and energy consumption targets set by council "will be extremely challenging."
"Our findings suggest that accelerating the rate of deep retrofits in Windsor (and Canada) will require substantial investments from federal and provincial governments," wrote a consultant in a market validation study.
"Windsor is currently on track to miss the climate targets set out in its Community Energy Plan and will struggle to meet them without further investment in residential deep retrofit incentive programs like Canada Greener Homes."
Meeting Windsor's 2041 climate targets would require 80 per cent of homes in the city become more energy efficient, but the market validation study found it's likely it would only see 10 per cent of homes retrofitted using the program in that timeline.
The study found there are enough contractors to complete the work in the launch of the program, however, also found the proposed uptake was "overly aggressive, as they overestimated participation when compared with utility and government retrofit programs."
"Even if we were to execute the program in its entirety," said commissioner of economic development Jelena Payne.
"We would still not be able to meet the targets that have been identified by upper levels of government and city council."
Citizens group, councillor want the program implemented
Derek Coronado, the executive director of Citizens Environment Alliance Southwestern Ontario, said the program should be supported by council to help people take action in a climate crisis.
He said the city has great plans but they need to be acted on to see results
"The city has not followed through on the important things of taking climate action seriously and that means implementing the stages of your plan that you need to implement," said Coronado.
He said the program, if implemented, would create work for contractors and should be looked at as an economic development tool as well as a way to slow climate change.
"Time and time again administration reports have said the most costly aspect of climate change is deferring, delaying or not dealing with climate change up front," said Coronado.
"That's exactly what the city has been doing. It's actually kicking the cost down the road."
Staff are asking council to receive the report and not implement the program but instead ask the federal government for more money to help cover costs.
Coun. Kieran McKenzie chaired the council committee that discussed the report on Wednesday and opposed that motion.
He highlighted how the program has been identified by staff as "fundamental to the success" of the city's climate action plans.
"We don't have other plans to get closer that I see to achieving our climate change goals," he said.
"We often don't make the hard decisions, and this is a hard one."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
21 hours ago
- Globe and Mail
Pfizer Q2 2025 Earnings: Strong Growth Amid Challenges
Pfizer Inc ((PFE)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pfizer's recent earnings call painted a picture of strong financial and operational performance in the second quarter of 2025. The company reported significant revenue growth, driven by key products and advancements in research and development. Despite these positive developments, Pfizer acknowledged challenges in certain product lines and potential impacts from ongoing policy discussions. The overall sentiment was optimistic, but tempered by uncertainties related to COVID-19 revenues and geopolitical factors. Record Revenue Growth Pfizer achieved a 10% operational increase in revenue for the second quarter of 2025, totaling $14.7 billion. This growth was fueled by the strong performance of key products such as Vyndaqel, Comirnaty, PAXLOVID, Padcev, and Eliquis, underscoring the company's successful commercial strategy and market leadership. Strong R&D Pipeline Progress The earnings call highlighted significant advancements in Pfizer's research and development pipeline. Promising developments in Elrexfio, Sigvotatug Vedotin, and Hympavzi were noted, indicating potential growth opportunities in the oncology and hematology markets. These advancements are expected to bolster Pfizer's future product offerings. Improved Financial Outlook Pfizer raised its full-year adjusted EPS guidance, reflecting strong year-to-date performance and favorable foreign exchange impacts. This improved financial outlook is a testament to the company's robust top-line performance and effective cost management strategies. Operational and Cost Efficiency The company reported an 8% operational decrease in total adjusted operating expenses, attributed to reduced marketing spend and pipeline optimization. These efficiencies have led to robust operating margins, enhancing Pfizer's overall financial health. Successful Commercial Strategy Pfizer maintained market leadership in key products like Eliquis and Vyndaqel, supported by strong international growth and effective engagement strategies. This successful commercial approach continues to drive the company's revenue growth and market presence. Challenges with IBRANCE and Seagen Products The earnings call acknowledged declines in IBRANCE and competitive pressures on Seagen products such as ADCETRIS and TUKYSA. These challenges have impacted growth in these segments, highlighting areas where Pfizer may need to focus on strategic improvements. Potential Policy and Tariff Impacts Ongoing discussions with the U.S. government regarding Most Favored Nation (MFN) policies and tariffs were mentioned as sources of uncertainty. These discussions could potentially impact Pfizer's future revenue and pricing strategies, adding a layer of complexity to the company's operational landscape. COVID-19 Revenue Uncertainty Despite a strong initial performance, Pfizer expressed uncertainty regarding COVID-19 vaccine and treatment revenues for the second half of the year. This uncertainty has led to a derisking of guidance, reflecting the unpredictable nature of the pandemic's impact on the company's financials. Forward-Looking Guidance Pfizer's forward-looking guidance included an increase in its adjusted diluted EPS guidance for the full year, driven by strong year-to-date performance. The company reported a 10% operational revenue increase to $14.7 billion and adjusted diluted earnings per share of $0.78, surpassing expectations. Pfizer emphasized its strategic priorities, including expanding its R&D portfolio and leveraging technological advancements to enhance margins and productivity gains, positioning the company for continued growth. In conclusion, Pfizer's earnings call reflected a strong financial performance in the second quarter of 2025, with significant revenue growth and advancements in R&D. While the overall sentiment was positive, challenges remain in certain product lines and potential policy impacts. The company's forward-looking guidance suggests continued growth, supported by strategic priorities and operational efficiencies.


Globe and Mail
2 days ago
- Globe and Mail
Contineum (CTNM) Q2 R&D Jumps 78%
Key Points GAAP net loss per share widened to $(0.62) in Q2 2025, missing analyst GAAP EPS estimates by $0.18, driven by a sharp rise in research and development expenses. R&D expenses surged 78%, reflecting increased investment in clinical pipeline programs, while cash reserves stood at $175.5 million. These 10 stocks could mint the next wave of millionaires › Contineum Therapeutics (NASDAQ:CTNM), a clinical-stage biotechnology company focused on developing treatments for serious diseases such as pulmonary fibrosis, multiple sclerosis, and depression, released its second quarter fiscal 2025 results on August 5, 2025. The most notable news in the earnings release was a wider GAAP net loss per share of $(0.62), missing the estimate of $(0.44). Research and development expenses (GAAP) saw a sharp rise as the company continued to advance its clinical pipeline. Management reported a robust cash position of $175.5 million as of June 30, 2025. Overall, the period reflected ongoing progress in pipeline development, but came with significantly higher spending and a continued absence of commercial revenue. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) ($0.62) ($0.44) ($0.39) (-59.0%) Revenue N/A $7.5 million N/A — Research and Development Expense $14.1 million $7.9 million 78.5% General and Administrative Expense $3.8 million $3.0 million 26.7% Source: Analyst estimates for the quarter provided by FactSet. Business Overview and Key Success Factors Contineum Therapeutics develops small molecule therapies for diseases with high unmet medical need. Its clinical programs focus on two main drug candidates: PIPE-791, an oral treatment being studied for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain; and PIPE-307, a selective M1R antagonist for use in depression and relapsing-remitting multiple sclerosis (RRMS). The company's pipeline also includes earlier-stage assets like CTX-343, a peripherally restricted LPA1R antagonist. Contineum has centered its business on advancing clinical trials for PIPE-791 and PIPE-307. Key success factors for the company include achieving positive clinical trial results, securing regulatory approvals, maintaining strategic partnerships (particularly with Johnson & Johnson for PIPE-307), and ensuring sufficient cash to fund ongoing development. A core part of its strategy relies on addressing conditions such as IPF and RRMS, where few effective therapies are available. Quarter Highlights and Financial Developments Contineum significantly increased its investment in research and development. This sharp rise was tied to the progression of clinical trials for both PIPE-791 and PIPE-307 and expanded workforce costs to support these activities. General and administrative expenses also increased, primarily due to higher stock-based compensation and salaries. GAAP net loss increased compared to the prior-year quarter. The absence of significant top-line revenue is typical for pre-commercial biotechnology companies at this stage. Management highlighted that all ongoing spending aligns with planned development milestones, focusing resources on advancing the pipeline rather than generating current sales. Operationally, the most notable achievements included advancing PIPE-791 in multiple indications. PIPE-791 is an oral drug designed to block LPA1R, a receptor implicated in the progression of fibrotic and neurodegenerative disorders. Management completed chronic toxicity studies for PIPE-791 and advanced plans for regulatory filings to begin a global Phase 2 trial for IPF later in 2025. Patient dosing started in a Phase 1b trial for chronic pain in March 2025, with results expected in the first half of 2026. The company postponed the planned Phase 2 study in progressive multiple sclerosis, choosing to concentrate resources on IPF instead. PIPE-307, intended for both RRMS and major depressive disorder (MDD), is in the VISTA Phase 2 proof-of-concept trial in RRMS. Top-line data are expected in the fourth quarter of 2025. Separately, Johnson & Johnson, through its Janssen business, launched recruitment in December 2024 for a Phase 2 trial testing PIPE-307 in adults with MDD. No new partnership deals or milestone payments were reported during the quarter. Strategic Focus, Program Prioritization, and Cash Updates Contineum made several program prioritization decisions during the period. It postponed starting clinical trials for PIPE-791 in PrMS and the first-in-human studies for CTX-343, focusing its resources on the largest near-term market opportunity in IPF. The company ended the quarter with $175.5 million in cash, cash equivalents, and marketable securities. This cash position should enable Contineum to fund operations through 2027, according to management. In July 2025, the company generated approximately $8.4 million in additional cash through an at-the-market stock offering, issuing 2,122,000 shares. The cash level reduces short-term financing risk, but ongoing operating losses and persistent R&D investment mean further funding might be required if programs take longer or cost more than anticipated. Management reaffirmed its focus on advancing the most promising pipeline programs and signaled no change in strategic partnerships or cash material events aside from the ATM offering. The pipeline's pace and development depend heavily on positive results from ongoing and upcoming clinical trials, particularly for PIPE-791 in IPF and PIPE-307 in RRMS and MDD. The company did not announce or adjust any dividend. Outlook and Guidance Contineum did not provide explicit guidance or financial forecasts for the next quarter or the remainder of fiscal 2025. Management referenced its strong cash position as sufficient to support planned development activities through 2027 but did not give revenue, expense, or earnings targets. Looking ahead, investors will likely track the timing and outcomes of the planned clinical milestones for PIPE-791 and PIPE-307, enrollment trends, and any updates on delayed programs or additional partnership deals. Risks remain tied to clinical trial outcomes, future cash burn trends, and the company's ability to access additional non-dilutive funding if needed. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025


Cision Canada
30-07-2025
- Cision Canada
Univar Solutions Honors Leading Transportation Solution Providers
"Each year I have the privilege of acknowledging the carriers who help our customers and suppliers through a focus on safety and responsiveness," said Rob McRae, the Vice President of Transportation, North America for Univar Solutions. "While the carrier industry is very process driven, exceptional transportation solution provider performance requires creative and innovative solutions, with a strong bias on timely communication, which each of these honorees have demonstrated for our industry." The annual awards comprise of honoring the regional, bulk, truckload, and less-than-truckload (LTL) carriers of the year for being a valued partner as Univar Solutions offers reliability that delivers through a commitment to safety, service, and expertise that moves customers and suppliers forward. The 2025 award segment honorees include the following. LTL Carrier of the Year: R+L Carriers Truckload Carrier of the Year: Echo Global Logistics Bulk Carrier of the Year: MC Tank Transport United States East Region Carrier of the Year: Southeastern Freight Lines United States West Region Carrier of the Year: James J. Williams Bulk Service Transport Canada East Region Carrier of the Year: Contrans Vrac Incorporated Canada West Region Carrier of the Year: Caron Transportation Systems Vendor Partner of the Year: Goodship Additionally, each year the Most Valuable Partner (MVP) honor is awarded to the carrier that exceeds expectations through creative solutions to enhance the customer experience. For 2025 the Univar Solutions MVP carrier is Barto Trucking. "My sincerest appreciation to our entire carrier network of transportation solution providers and congratulations to our list of esteemed honorees for driving safety and on-time delivery performance as well as exceeding our rigorous service criteria, volume commitments, data connectivity, and responsiveness in communications," noted Travis Vedral, Senior Director of Transportation, Systems, and Strategies for Univar Solutions. "Our annual carrier event is a special occasion to both honor and recognize the many talented teams who help keep our supply chains moving across North America as well as set the stage for what comes next as Univar Solutions helps our customers and suppliers grow and we fulfill our purpose to help keep communities healthy, fed, clean, and safe." About Univar Solutions Univar Solutions is a leading global specialty chemical and ingredient distributor representing a premier portfolio from the world's leading producers. With the industry's largest private transportation fleet and technical sales force, unparalleled logistics know-how, deep market and regulatory knowledge, formulation and recipe development, and leading digital tools, the Company is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. While fulfilling its purpose to help keep communities healthy, fed, clean, and safe, Univar Solutions is committed to helping customers and suppliers innovate and focus on Growing Together. Learn more at About Univar Solutions Chemical Distribution & Services division At Univar Solutions, our Chemical Distribution & Services division is focused on Reliability that Delivers. This means more than on-time shipments—it is a commitment to safety that leads the way, service that goes the distance, and expertise that moves customers and suppliers forward. With industry leading safety standards, a best-in-class on-time delivery rate, and over a century of knowledge engineered for impact, Univar Solutions offers a level of collaboration and predictability through chemistry that Grows, Flows, and Knows the application. Learn more at Forward-Looking Statements and Information This communication contains "forward-looking statements" under applicable law regarding financial and operating items relating to the Company's business. Forward-looking statements generally can be identified by words such as "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates," "anticipates" or other comparable terms. All forward-looking statements made in this communication are qualified by this cautionary language. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control, that could result in expectations not being realized or could otherwise materially and adversely affect the Company's business, financial condition, results of operations or cash flows. Although the forward-looking statements are based on what management believes to be reasonable assumptions, we caution you that the forward-looking information presented in this communication is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this communication. For additional information regarding factors that could affect the Company, please see the Company's most recent annual report and other financial reports, including the information set forth under the caption "Risk Factors." Any forward-looking statements represent the Company's views only as of the date of this communication and should not be relied upon as representing the Company's views as of any subsequent date, and the Company undertakes no obligation, other than as may be required by law, to update any forward-looking statement.